NEW YORK and MUMBAI (October 28, 2019)—Non-profit drug developer TB Alliance has granted Macleods Pharmaceuticals Limited a non-exclusive license to manufacture the anti-TB drug pretomanid as part of the three-drug “BPaL” regimen. Pending regulatory approvals, Macleods has agreed to commercialize the anti-tuberculosis (TB) medicine in approximately 140 countries and territories.
“TB Alliance is committed to ensuring an affordable, sustainable and competitive market for all our new TB products,” said Mel Spigelman, president and CEO, TB Alliance. “We are proud to partner with Macleods, which has a strong record of delivering high-quality, affordable tuberculosis medicines.”
“Our zeal to bridge unmet needs ensures that we make Tomorrow’s Medicine Available Today. This important collaboration with TB Alliance will ensure accessibility of pretomanid in countries where it is needed the most,” said Vijay Agarwal, business development director at Macleods.
TB Alliance has previously collaborated with Macleods on the introduction of child-friendly formulations of first-line TB medicines. Since launched in 2015, more than one million treatment courses have been ordered by 94 countries, which represent approximately 95% of the global childhood TB burden.1
About TB Alliance
TB Alliance is a not-for-profit organization dedicated to finding faster-acting and affordable drug regimens to fight TB. Through innovative science and with partners around the globe, we aim to ensure equitable access to faster, better TB cures that will advance global health and prosperity. TB Alliance operates with support from Australia’s Department of Foreign Affairs and Trade, Bill & Melinda Gates Foundation, Cystic Fibrosis Foundation, European & Developing Countries Clinical Trials Partnership, Germany’s Federal Ministry of Education and Research through KfW, Global Health Innovative Technology Fund, Indonesia Health Fund, Irish Aid, Medical Research Council (United Kingdom), National Institute of Allergy and Infectious Disease, Netherlands Ministry of Foreign Affairs, Rockefeller Foundation, United Kingdom Department for International Development, and the United States Agency for International Development.
About Macleods Pharmaceuticals Limited
A vertically integrated generic pharmaceutical company, highly focused on essential medicines, which are needed for treatment of TB, HIV and Malaria. With supplies made in over 140 countries, our geographical presence ensures that we are able to respond to medical needs in most of the high burden countries. We remain true to our mission to provide affordable care to patients, worldwide.
1. Data on file. Macleods Pharmaceuticals Limited